TPX-0046 is an orally bioavailable TKI with a novel macrocyclic structure that is being developed as a RET kinase inhibitor. TPX-0046 is being evaluated in the ongoing Phase 1/2 SWORD-1 clinical trial for the treatment of advanced solid tumors with RET gene alterations.

Turning Point Therapeutics is now a
Bristol Myers Squibb company

Select OK for information about Turning Point Therapeutics.

Select BMS to learn more about Bristol Myers Squibb